UnknownNot applicableNCT05239130
Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- I.R.A. Istituto Ricerche Applicate S.p.A.
- Principal Investigator
- Mihaela FratilaSCM Dr. Rosu
- Intervention
- Auralya(device)
- Enrollment
- 48 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2022 – 2022
Study locations (1)
- SCM Dr. Rosu, Timișoara, Timiș County, Romania
Collaborators
Opera CRO, a TIGERMED Group Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05239130 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024University of Michigan
- RECRUITINGNCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryAmryt Pharma
See all trials for Lipodystrophy due to peptidic growth factors deficiency →